GBT Global Blood Therapeutics


Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
CarbonClimateContaminantEnvironmentEnvironmentalEnvironmental ProtectionLEEDLife CycleLifecycleMaterialsNatureOffsetPackagePackagingPandemicRaw MaterialsRecyclingRegenerativeToxicWasteWaterAccessAsianBenefitsBlackCalifornia Consumer Privacy ActCharitableCommunityCultureCustomerCyberCyber SecurityCybersecurityData PrivacyData SecurityDeathDisabilityDiversityDiversity and InclusionDrug PricingEmployeeEmployee EngagementEngagementEthnicEthnicityGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHispanicHuman CapitalHuman ResourcesInjuredInjuriesInjuryMinorityPay EquityPay ParityPerquisitesPrivacyProduct SafetyRecallRecruitRecruitmentReimbursementResource GroupRetentionRetirementSafetySatisfactionSexual HarassmentSkilledSkillsSocialSocietyStakeholderSupplierSupply ChainTalentTrainingUnionVolunteerWomenWorkersWorkforceAnti-corruptionAntitrustAssessmentAssuranceAttorneys GeneralAuditBonusBribeBriberyChronicClass Action LawsuitClassifiedClassified BoardClawbackCommitmentConflict of InterestCorporate GovernanceCorporate PurposeDepartment ofESGEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIncentivizeIndependenceIndependentInnovationInnovativeInvestigationLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityMissionOverseeOversightPerquisitePledgingPurposeQuality StandardR&DRecoupReputationReputationalResearch and DevelopmentResponsibilityResponsibleSelf-evaluationSpecial MeetingStrategySupermajoritySustainabilitySustainableTargetsTaxTenureTransparencyVoting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The proposals set forth below were submitted to the stockholders at the 2021 Annual Meeting of Stockholders, or Annual Meeting, of Global Blood Therapeutics, Inc., or Company, held on June 17, 2021, with each such proposal described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2021, or Proxy Statement.

The number of shares of common stock entitled to vote at the Annual Meeting was 62,266,753. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 45,159,323. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.

Proposal 1 – Election of Directors

The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors to hold office until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified.

Director NomineeVotes ForVotes Withheld
Scott W. Morrison29,333,50910,668,327
Deval L. Patrick28,898,51911,103,317
Mark L. Perry29,322,42110,679,415

There were 5,157,487 broker non-votes regarding this proposal.

Proposal 2 – Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers as Disclosed in the Proxy Statement

The Company’s stockholders did not approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

Votes ForVotes AgainstAbstentions

There were 5,157,487 broker non-votes regarding this proposal.

Proposal 3 – Ratification of Appointment of Independent Registered Accounting Firm

The Company’s stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.

Votes ForVotes AgainstAbstentions

There were no broker non-votes regarding this proposal.